SRI International was awarded $15.5 million to provide preclinical services to NIAID to support development of drugs and vaccines for HIV and AIDS.
Under the terms of this agreement, SRI will provide toxicology, pharmacology, pharmacokinetics, toxicogenomics, and other services. The collaborators believe that this will ultimately help the NIAID with IND applications.
This is an adjunct to a preexisting NIAID contract held by SRI since 1991. Under the terms of the original agreement, SRI has been providing preclinical services for the past 16 years, for more than 200 drugs and vaccines at various stages of development.